As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the low priced stocks to buy with high upside potential. On December 12, Bank of America raised the firm’s price target on Ocular Therapeutix to $21 ...

DEXTENZA ® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors in Ocular Therapeutix Inc (Symbol: OCUL) saw new options become available today, for the April 2026 expiration. One of the key data points that goes into the price an option buyer is willing ...

Investors in Ocular Therapeutix Inc (Symbol: OCUL) saw new options begin trading this week, for the November 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

Wondering if Ocular Therapeutix at around US$7.78 is offering fair value right now, or if the recent volatility is masking a better entry point for long term investors. The stock has seen a 12.4% ...

Ocular Therapeutix Inc (NASDAQ:OCUL) shares are trading lower by 13.3% to $7.63 Monday afternoon after the company reported worse-than-expected first-quarter financial results. What To Know: Ocular ...

Ocular Therapeutix, Inc. (OCUL) stock price is 10.27 and Ocular Therapeutix, Inc. (OCUL) 10-day simple moving average is 9.88. Ocular Therapeutix, Inc. (OCUL) stock price is 10.27 and Ocular ...

Shares of ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) fell 8.6% in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about ...

Ocular Therapeutix (OCUL) shares ended the last trading session 6.1% higher at $11.07. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.